DOCSLIB.ORG

Macrolides: from Toxins to Therapeutics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Macrolides: from Toxins to Therapeutics toxins Review Macrolides: From Toxins to Therapeutics Kiersten D. Lenz , Katja E. Klosterman , Harshini Mukundan and Jessica Z. Kubicek-Sutherland * Physical Chemistry and Applied Spectroscopy, Chemistry Division, Los Alamos National Laboratory, Los Alamos, NM 87545, USA; [email protected] (K.D.L.); [email protected] (K.E.K.); [email protected] (H.M.) * Correspondence: [email protected] Abstract: Macrolides are a diverse class of hydrophobic compounds characterized by a macrocyclic lactone ring and distinguished by variable side chains/groups. Some of the most well characterized macrolides are toxins produced by marine bacteria, sea sponges, and other species. Many marine macrolide toxins act as biomimetic molecules to natural actin-binding proteins, affecting actin polymerization, while other toxins act on different cytoskeletal components. The disruption of natural cytoskeletal processes affects cell motility and cytokinesis, and can result in cellular death. While many macrolides are toxic in nature, others have been shown to display therapeutic properties. Indeed, some of the most well known antibiotic compounds, including erythromycin, are macrolides. In addition to antibiotic properties, macrolides have been shown to display antiviral, antiparasitic, antifungal, and immunosuppressive actions. Here, we review each functional class of macrolides for their common structures, mechanisms of action, pharmacology, and human cellular targets. Keywords: macrolide; toxin; antibiotic; antifungal; antiviral; antiparasitic; immunosuppressant Key Contribution: The wide range of bioactivities found in the diverse class of macrolides has promising implication for novel drug discovery. This review highlights the structure, mechanisms of action, pharmacology and human cellular interactions of a variety of macrolide compounds that may have potential therapeutic applications. Citation: Lenz, K.D.; Klosterman, K.E.; Mukundan, H.; Kubicek-Sutherland, J.Z. Macrolides: From Toxins to Therapeutics. Toxins 1. Introduction 2021, 13, 347. https://doi.org/ The study of macrolides over the past few decades has revealed a varied group 10.3390/toxins13050347 of molecules with a range of structures and functions. Macrolides are hydrophobic compounds characterized by a macrocyclic lactone ring that typically contains at least Received: 12 April 2021 12 elements, while the remaining structure varies greatly between different classes of Accepted: 8 May 2021 molecules [1,2]. Published: 12 May 2021 Many macrolides have been discovered that display pharmaceutical properties, giving them potential as antibiotic, antiviral, antiparasitic, antimycotic, or immunosuppressant Publisher’s Note: MDPI stays neutral drugs [2,3]. While naturally produced macrolides may have limited use as drugs due to with regard to jurisdictional claims in published maps and institutional affil- their instability in stomach acid, poor pharmacokinetics, and adverse side effects, synthetic iations. macrolide derivatives have been developed to overcome these issues [1]. Many macrolides also exhibit toxic bioactivity, which may be a cause of the adverse side effects observed in response to the administration of macrolide drugs. Indeed, one of the largest classes of macrolides is toxins, many of which are produced from marine sources [4]. On the other hand, some macrolide mechanisms of toxicity have been manipulated for use in Copyright: © 2021 by the authors. therapeutic applications. Licensee MDPI, Basel, Switzerland. The focus of this review was to compare and contrast five major functional classes of This article is an open access article distributed under the terms and macrolides from a variety of natural sources: toxins, antibiotics, antivirals/antiparasitics, conditions of the Creative Commons antifungals, and immunosuppressants. Each subclass has been reviewed for structural Attribution (CC BY) license (https:// similarities, mechanisms of action, pharmacology, and side effects in human beings. For creativecommons.org/licenses/by/ a comprehensive review of macrolides from marine sources, see the review written by 4.0/). Zhang et al. in 2021 [4]. Toxins 2021, 13, 347. https://doi.org/10.3390/toxins13050347 https://www.mdpi.com/journal/toxins Toxins 2021, 13, 347 2 of 27 2. Macrolide Classes 2.1. Toxins Toxins 2021, 13, x FOR PEER REVIEW Macrolide toxins originating from marine and microbial sources represent a vast3 of 37 library of chemical structures with varying mechanisms of toxicity. Marine macrolide toxins are of particular interest, as the number of known toxins has increased greatly over the past 50 years.Table Increasing1. Structure of knowledge Macrolide Toxins. of the biochemistry of these compounds has Toxins 2021, 13, x FOR PEER REVIEWexplained a wide range of toxic effects, from quick paralysis to more gradual changes3 of 37 in target cells. Marine macrolide toxins have also been of interest due to their potential Macrolide Class Compoundstherapeutic propertiesSource against * cancer and fungal or parasiticExample infections, Structure and their ability to act as immunosuppressants [3,4]. Toxins produced by bacterial species, such as the Table 1. Structure of Macrolide Toxins. mycolactones from Mycobacterium ulcerans, also have a wide range of effects on host cells, Toxins 2021, 13, x FOR PEER REVIEWmany of which have yetto be discovered [5]. 3 of 37 Kabiramide C Macrolide Class Compounds Source * Example Structure Kabiramides2.1.1. Structures Hexabranchus sp. The structuresTable 1. of Structure the macrolide of Macrolide toxins Toxins. reviewed in this paper are variable; however, Ulapualidesthe majority ofHexabranchus the structures sanguineus consist of two major components: (1) the macrocyclic ring, O O Trisoxazole- Kabiramide C which can vary in size, conjugated dienes, andO functionalN groups,O andOO (2) the acyclic side ring-containing Halichondramidechain, which is oftenChondrosia referred corticata to as the “tail”,N and can also vary in structure andN length Macrolide Class CompoundsKabiramides HexabranchusSource * sp. ExampleO Structure macrolides O between different toxins. The major subclassesN of macrolideO toxins are summarized in O Jaspisamides Jaspis sp. OH UlapualidesTable1. Hexabranchus sanguineus O O O O Trisoxazole- ONH O N 2 O OO Table 1. Structure of Macrolide Toxins. Kabiramide C ring-containing Halichondramide Chondrosia corticata N N O macrolides Kabiramides Hexabranchus sp. O Macrolide Class Compounds Source *N ExampleO Structure Mycalolides Mycale sp. O Jaspisamides Jaspis sp. OH KabiramideO C Ulapualides Hexabranchus sanguineus O O O ONH2 Trisoxazole- Kabiramides Hexabranchus sp. O N O OO Ulapualides Hexabranchus sanguineus Swinholide A ring-containing Halichondramide Chondrosia corticata N N Trisoxazole-ring- O Halichondramide Chondrosia corticata O macrolides Mycalolides Mycale sp. H containing macrolides N O Jaspisamides Jaspis sp. O Jaspisamides Jaspis sp. OH Mycalolides Mycale sp. O O H O O HO HO ONH Swinholide2 A HO Swinholides Theonella swinhoei O OH Swinholide A H O Mycalolides Mycale sp. O O Macrodiolides Ankaraholides Geitlerinema sp. O O H O O HO HO O OH O OH HO Swinholides Theonella swinhoei O OH Swinholide A O OH OH O O Swinholides Theonella swinhoei H Macrodiolides H O O Macrodiolides AnkaraholidesAnkaraholides Geitlerinema sp. O O O O H H O OH HO HO O OH HO Swinholides Theonella swinhoei O OH OH OH O O H O O O O Macrodiolides Ankaraholides Geitlerinema sp. H O ReidispongiolideO A OH O Reidispongiolide AOH OOO Reidispongiolides Reidispongia coreulea OH OH O Reidispongiolides Reidispongia coreulea H O DiterpeneDiterpene macrolactones mac- O OOO SphinxolidesSphinxolides Neosiphonia superstes ReidispongiolideH A H rolactones N O O O O OOO Reidispongiolides Reidispongia coreulea OO Diterpene mac- Sphinxolides Neosiphonia superstes O OOO H rolactones N O O O ReidispongiolideO A OO Jasplakinolides Jaspis johnstoni OOOJasplakinolide Other Reidispongiolides Reidispongia coreulea Diterpenemacrolides mac- SphinxolidesLatrunculins LatrunculiaNeosiphonia magnificasuperstes O OOO H rolactones N O O O O JasplakinolidesSpongistatin JaspisHyrtios johnstoni erecta Jasplakinolide Other OO macrolides Latrunculins Latrunculia magnifica Spongistatin Hyrtios erecta Jasplakinolides Jaspis johnstoni Jasplakinolide Other macrolides Latrunculins Latrunculia magnifica Spongistatin Hyrtios erecta Toxins 2021, 13, 347 3 of 27 Toxins 2021, 13, x FOR PEER REVIEW 4 of 37 Table 1. Cont. Macrolide Class Compounds Source * Example Structure Aplyronine Aplysia kurodai Jasplakinolide Venturicidins Streptomyces sp. Br HO NH Jasplakinolides Jaspis johnstoni MycolactoneLatrunculins MycobacteriumLatrunculia magnifica ulcerans H Spongistatin Hyrtios erecta N Other macrolides HalichondrinsAplyronine HalichondriaAplysia kurodai okadai O N Venturicidins Streptomyces sp. O Mycolactone Mycobacterium ulcerans O O Halichondrins Halichondria okadai O NH * Toxins may be produced by multiple species; one representative example is provided. 2.1.2. Mechanisms of Action * Toxins mayInhibition be produced of Actin by multiple Polymerization species; one representative example is provided. Many of the macrolide toxins discussed in this review directly interact with major components2.1.2. Mechanisms of the eukaryotic of Action cell cytoskeleton, including actin, by causing either an inhi- bition or an increase in polymerization. Cytoskeletal proteins play vital roles in eukaryotic cellInhibition health, andof Actin disruption Polymerization of the natural formation of these proteins
Load more

Recommended publications
  • National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): a Cross-Sectional Study
    Tropical Medicine and Infectious Disease Article National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): A Cross-Sectional Study Joseph Sam Kanu 1,2,* , Mohammed Khogali 3, Katrina Hann 4 , Wenjing Tao 5, Shuwary Barlatt 6,7, James Komeh 6, Joy Johnson 6, Mohamed Sesay 6, Mohamed Alex Vandi 8, Hannock Tweya 9, Collins Timire 10, Onome Thomas Abiri 6,11 , Fawzi Thomas 6, Ahmed Sankoh-Hughes 12, Bailah Molleh 4, Anna Maruta 13 and Anthony D. Harries 10,14 1 National Disease Surveillance Programme, Sierra Leone National Public Health Emergency Operations Centre, Ministry of Health and Sanitation, Cockerill, Wilkinson Road, Freetown, Sierra Leone 2 Department of Community Health, Faculty of Clinical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone 3 Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, 1211 Geneva, Switzerland; [email protected] 4 Sustainable Health Systems, Freetown, Sierra Leone; [email protected] (K.H.); [email protected] (B.M.) 5 Unit for Antibiotics and Infection Control, Public Health Agency of Sweden, Folkhalsomyndigheten, SE-171 82 Stockholm, Sweden; [email protected] 6 Pharmacy Board of Sierra Leone, Central Medical Stores, New England Ville, Freetown, Sierra Leone; [email protected] (S.B.); [email protected] (J.K.); [email protected] (J.J.); [email protected] (M.S.); [email protected] (O.T.A.); [email protected] (F.T.) Citation: Kanu, J.S.; Khogali, M.; 7 Department of Pharmaceutics and Clinical Pharmacy & Therapeutics, Faculty of Pharmaceutical Sciences, Hann, K.; Tao, W.; Barlatt, S.; Komeh, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown 0000, Sierra Leone 8 J.; Johnson, J.; Sesay, M.; Vandi, M.A.; Directorate of Health Security & Emergencies, Ministry of Health and Sanitation, Sierra Leone National Tweya, H.; et al.
    [Show full text]
  • Erythromycin* Class
    Erythromycin* Class: Macrolide Overview Erythromycin, a naturally occurring macrolide, is derived from Streptomyces erythrus. This macrolide is a member of the 14-membered lactone ring group. Erythromycin is predominantly erythromycin A, but B, C, D and E forms may be included in preparations. These forms are differentiated by characteristic chemical substitutions on structural carbon atoms and on sugars. Although macrolides are generally bacteriostatic, erythromycin can be bactericidal at high concentrations. Eighty percent of erythromycin is metabolically inactivated, therefore very little is excreted in active form. Erythromycin can be administered orally and intravenously. Intravenous use is associated with phlebitis. Toxicities are rare for most macrolides and hypersensitivity with rash, fever and eosinophilia is rarely observed, except with the estolate salt. Erythromycin is well absorbed when given orally. Erythromycin, however, exhibits poor bioavailability, due to its basic nature and destruction by gastric acids. Oral formulations are provided with acid-resistant coatings to facilitate bioavailability; however these coatings can delay therapeutic blood levels. Additional modifications produced better tolerated and more conveniently dosed newer macrolides, such as azithromycin and clarithromycin. Erythromycin can induce transient hearing loss and, most commonly, gastrointestinal effects evidenced by cramps, nausea, vomiting and diarrhea. The gastrointestinal effects are caused by stimulation of the gastric hormone, motilin, which
    [Show full text]
  • Identification of Macrolide Antibiotic-Binding Human P8 Protein
    J. Antibiot. 61(5): 291–296, 2008 THE JOURNAL OF ORIGINAL ARTICLE ANTIBIOTICS Identification of Macrolide Antibiotic-binding Human_p8 Protein Tetsuro Morimura, Mio Hashiba, Hiroshi Kameda, Mihoko Takami, Hirokazu Takahama, Masahiko Ohshige, Fumio Sugawara Received: December 10, 2007 / Accepted: May 1, 2008 © Japan Antibiotics Research Association Abstract Clarithromycin is a macrolide antibiotic that is widely used in clinical medicine. Macrolide antibiotics Introduction such as clarithromycin specifically bind to the 50S subunit of the bacterial ribosome thereby interfering with protein Launched in 1990 by Abbott Laboratories, clarithromycin biosynthesis. A selected peptide sequence from our former A (CLA: synonym of 6-O-methylerythromycin, 1) [1] is a study, composed of 19 amino acids, which was isolated macrolide antibiotic that is commonly used to treat a from a phage display library because of its ability to bind variety of human bacterial infections. Macrolide clarithromycin, displayed significant similarity to a portion antibiotics, represented by erythromycin A (ERY, 2) and its of the human_p8 protein. The recombinant p8 protein structural homologues, specifically bind to the bacterial binds to biotinylated-clarithromycin immobilized on a 50S ribosomal subunit resulting in the inhibition of streptavidin-coated sensor chip and the dissociation bacterial protein biosynthesis [2]. CLA (1) is also constant was determined. The binding of recombinant p8 commonly used to target gastric Helicobacter pylori, which protein to double-stranded DNA was inhibited by is implicated in both gastric ulcers and cancer [3]. biotinylated-clarithromycin, clarithromycin, erythromycin Numerous studies to develop novel pharmaceutical and azithromycin in gel mobility shift assay. applications for macrolide antibiotics, including CLA (1), Dechlorogriseofulvin, obtained from a natural product ERY (2) and azithromycin (AZM, 3), have been published screening, also inhibited human p8 protein binding to [4].
    [Show full text]
  • Women Chemists in the National Inventors' Hall Of
    50 Bull. Hist. Chem., VOLUME 34, Number 1 (2009) WOMEN CHEMISTS IN THE NATIONAL INVENTORS’ HALL OF FAME: THEIR REMARKABLE LIVES AND THEIR AWARD-WINNING RESEARCH Mary Virginia Orna, College of New Rochelle The National Inventors’ Hall of Fame (NIHF) celebrates other individual or with a team, taking advantage of a the creative and entrepreneurial spirit of great inventors serendipitous event, curiosity, creativity, innovation, and by showcasing exhibits and presentations that allow a passion for chemistry. The qualities most applicable to visitors to experience the excitement of discovery, cre- each individual will be stressed in each section. ativity, and imagination. Founded in 1972 and located in Akron, Ohio, USA, the Hall of Fame is dedicated to Collaborative Efforts, Financial Straits: the individuals who conceived the great technologi- Rachel Fuller Brown and Gertrude Elion cal advances which the USA fosters through its patent system. Each year a Selection Committee composed of The lives and careers of two of the earliest inductees par- representatives from national scientific and technical allel one another in a remarkable way. Both Rachel Fuller organizations votes to select the most qualified inventors Brown (1898-1980), inducted posthumously in 1994 (2), from those nominated for the current year. To date, only and Gertrude Belle Elion (1918-1999), inducted in 1991 13 women of the more than 375 inventors thus honored (3), carried on their research in close collaboration with are members of the Hall of Fame, and of these 13, six one other scientist. are chemists (1): Rachel Fuller, Brown, Gertrude Belle Elion, Edith Flanigen, Stephanie Louise Kwolek, Helen Brown carried on a long-distance joint effort with Murray Free, and Patsy O’Connell Sherman.
    [Show full text]
  • MACROLIDES (Veterinary—Systemic)
    MACROLIDES (Veterinary—Systemic) This monograph includes information on the following: Category: Antibacterial (systemic). Azithromycin; Clarithromycin; Erythromycin; Tilmicosin; Tulathromycin; Tylosin. Indications ELUS EL Some commonly used brand names are: For veterinary-labeled Note: The text between and describes uses that are not included ELCAN EL products— in U.S. product labeling. Text between and describes uses Draxxin [Tulathromycin] Pulmotil Premix that are not included in Canadian product labeling. [Tilmicosin Phosphate] The ELUS or ELCAN designation can signify a lack of product Erythro-200 [Erythromycin Tylan 10 [Tylosin availability in the country indicated. See the Dosage Forms Base] Phosphate] section of this monograph to confirm availability. Erythro-Med Tylan 40 [Tylosin [Erythromycin Phosphate] General considerations Phosphate] Macrolides are considered bacteriostatic at therapeutic concentrations Gallimycin [Erythromycin Tylan 50 [Tylosin Base] but they can be slowly bactericidal, especially against Phosphate] streptococcal bacteria; their bactericidal action is described as Gallimycin-50 Tylan 100 [Tylosin time-dependent. The antimicrobial action of some macrolides is [Erythromycin Phosphate] enhanced by a high pH and suppressed by low pH, making them Thiocyanate] less effective in abscesses, necrotic tissue, or acidic urine.{R-119} Gallimycin-100 Tylan 200 [Tylosin Base] Erythromycin is an antibiotic with activity primarily against gram- [Erythromycin Base] positive bacteria, such as Staphylococcus and Streptococcus Gallimycin-100P Tylan Soluble [Tylosin species, including many that are resistant to penicillins by means [Erythromycin Tartrate] of beta-lactamase production. Erythromycin is also active against Thiocyanate] mycoplasma and some gram-negative bacteria, including Gallimycin-200 Tylosin 10 Premix [Tylosin Campylobacter and Pasteurella species.{R-1; 10-12} It has activity [Erythromycin Base] Phosphate] against some anaerobes, but Bacteroides fragilis is usually Gallimycin PFC Tylosin 40 Premix [Tylosin resistant.
    [Show full text]
  • Binding Site of Macrolide Antibiotics on the Ribosome: New Resistance Mutation Identifies a Specific Interaction of Ketolides with Rrna
    JOURNAL OF BACTERIOLOGY, Dec. 2001, p. 6898–6907 Vol. 183, No. 23 0021-9193/01/$04.00ϩ0 DOI: 10.1128/JB.183.23.6898–6907.2001 Copyright © 2001, American Society for Microbiology. All Rights Reserved. Binding Site of Macrolide Antibiotics on the Ribosome: New Resistance Mutation Identifies a Specific Interaction of Ketolides with rRNA 1 1 2 1 GEORGINA GARZA-RAMOS, † LIQUN XIONG, PING ZHONG, ‡ AND ALEXANDER MANKIN * Center for Pharmaceutical Biotechnology, University of Illinois, Chicago, Illinois 60607,1 and Infectious Disease Research, Abbott Laboratories, Abbott Park, Illinois 600642 Received 31 July 2001/Accepted 19 September 2001 Macrolides represent a clinically important class of antibiotics that block protein synthesis by interacting with the large ribosomal subunit. The macrolide binding site is composed primarily of rRNA. However, the mode of interaction of macrolides with rRNA and the exact location of the drug binding site have yet to be described. A new class of macrolide antibiotics, known as ketolides, show improved activity against organisms that have developed resistance to previously used macrolides. The biochemical reasons for increased potency of ketolides remain unknown. Here we describe the first mutation that confers resistance to ketolide antibiotics while leaving cells sensitive to other types of macrolides. A transition of U to C at position 2609 of 23S rRNA rendered E. coli cells resistant to two different types of ketolides, telithromycin and ABT-773, but increased slightly the sensitivity to erythromycin, azithromycin, and a cladinose-containing derivative of telithromycin. Ribosomes isolated from the mutant cells had reduced affinity for ketolides, while their affinity for erythro- mycin was not diminished.
    [Show full text]
  • Clinical Efficacy of Doxycycline for Treatment of Macrolide-Resistant
    antibiotics Article Clinical Efficacy of Doxycycline for Treatment of Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Children Hyunju Lee 1,2, Youn Young Choi 3, Young Joo Sohn 3 , Ye Kyung Kim 3, Mi Seon Han 4 , Ki Wook Yun 1,3 , Kyungmin Kim 2 , Ji Young Park 5 , Jae Hong Choi 6, Eun Young Cho 7 and Eun Hwa Choi 1,3,* 1 Department of Pediatrics, Seoul National University College of Medicine, Seoul 03080, Korea; [email protected] (H.L.); [email protected] (K.W.Y.) 2 Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam 13620, Korea; [email protected] 3 Department of Pediatrics, Seoul National University Children’s Hospital, Seoul 03080, Korea; [email protected] (Y.Y.C.); [email protected] (Y.J.S.); [email protected] (Y.K.K.) 4 Department of Pediatrics, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul 07061, Korea; [email protected] 5 Department of Pediatrics, Chung-Ang University Hospital, Seoul 06973, Korea; [email protected] 6 Department of Pediatrics, Jeju National University School of Medicine, Jeju 63241, Korea; [email protected] 7 Department of Pediatrics, Chungnam National University Hospital, Daejeon 35015, Korea; [email protected] * Correspondence: [email protected] Abstract: In areas with high prevalence of macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia, treatment in children has become challenging. This study aimed to analyze the efficacy Citation: Lee, H.; Choi, Y.Y.; Sohn, of macrolides and doxycycline with regard to the presence of macrolide resistance. We analyzed Y.J.; Kim, Y.K.; Han, M.S.; Yun, K.W.; children with MP pneumonia during the two recent epidemics of 2014–2015 and 2019–2020 from Kim, K.; Park, J.Y.; Choi, J.H.; Cho, four hospitals in Korea.
    [Show full text]
  • Macrolide Esterase-Producing Escherichia Coli Clinically Isolated in Japan
    VOL. 53 NO. 5, MAY2000 THE JOURNAL OF ANTIBIOTICS pp.516 - 524 Macrolide Esterase-producing Escherichia coli Clinically Isolated in Japan Akio Nakamura, Kyoko Nakazawa, Izumi Miyakozawa, Satoko Mizukoshi, Kazue Tsurubuchi, Miyuki Nakagawa, Koji O'hara* and Tetsuo Sawai Department of Microbial Chemistry, Faculty of Pharmaceutical Sciences, Chiba University, Chiba 263-8522, Japan (Received for publication January 25, 2000) Current Japanese clinical practice involves the usage of large amounts of newmacrolides such as clarithromycin and roxithromycin for the treatment of diffuse panbronchiolitis, Helicobacter pylori and Mycobacterium avium complex infections. In this study, the phenotypes, genotypes, and macrolide resistance mechanisms of macrolide-inactivating Escherichia coll recovered in Japan from 1996 to 1997, were investigated. The isolation rate of erythromycin A highly-resistant E. coli (MIC > 1600 /xg/ml) in Japan slightly increased from 0.5% in 1986 to 1.2% in 1997. In six macrolide-resistant strains, recovered from the strains collected for this study during 1996 to 1997, the inactivation of macrolide could be detected with or without added ATPin the assay system. The appearance of erythromycin A-inactivating enzyme independent of ATPwas novel from Japanese isolates, and the ]H NMRspectra of oleandomycin hydrolyzed by the three ATP-independent isolates were examined. It was clearly shown that the lactone ring at the position of C-13 was cleaved as 13-H signal in aglycon of oleandomycin upper shifted. These results suggested the first detection of macrolide-lactone ring-hydrolase from clinical isolates in Japan. These results suggested the first detection of an ATP-independent macrolide-hydrolyzing enzyme from Japanese clinical isolates.
    [Show full text]
  • Lisa Grillone, Ph.D
    Volume 8, Issue 2 March/April 2000 NEWSLETTER Mission Statement: The Association for Women in Science, Inc. (AWIS) is a non-profit organization dedicated to the achievement of equity and full participation of women in all areas of science and technology. Member Profile: Lisa Grillone, Ph.D. Meet our Corporate Sponsors Executive Director of Clinical Regulatory Affairs By Janice Payne Isis Pharmaceuticals By Christine Haws As Executive Director of Clinical Regulatory Affairs at Isis, Lisa Grillone, Ph.D. has the distinction of heading the drug development team that successfully brought the first antisense oligonucleotide compound through FDA approval. This scientific milestone opened up the possibility of antisense treatment for many human diseases. Agouron was a platinum sponsor of the 1999 Women in Bioscience Conference, and we are grateful for their support. Lisa was born, raised and educated in New York City. She Agouron was established in 1984 and was ranked as the largest graduated with a B.S. from St. John’s University and went on to San Diego biotech company by the San Diego Business Journal attain M.S. and Ph.D. degrees from NYU. Despite having spent in August of 1999. Agouron’s mission is to design, develop, and the past few years in San Diego, Lisa sees herself as a “diehard market drugs to treat cancer, AIDS, and other diseases. They Manhattan woman.” develop therapeutics using an approach known as protein structure-based drug design which involves determination of the Her decision to pursue a career in science began early in her life, 3-dimensional structure of a disease related protein and then around the age of twelve.
    [Show full text]
  • Mothers of Invention Female Ingenuity
    Mothers of Invention They say necessity is the mother of invention. But mothers are the mothers of these inventions for kids. Invention Inventor Year Alphabet blocks Adeline Whitney 1882 Ansa baby bottle Nickie Campbell 1984 Baby Einstein videos Julie Aigner-Clark 1997 Baby jumper Jane Wells 1872 Barney (the purple dinosaur) Sheryl Leach 1988 Careerpals dolls Linda Stockdale 1991 Diapers Maria Allen 1887 Disposable diapers Marion Donovan 1951 Flexible kite Gertrude Rogallo 1951 Folding crib Sarah Neal 1894 Infant carrier (Snugli) Agnes Auckerman & Ann Moore 1962 Movable doll eyes Beulah Henry 1935 School desk Anna Breadin 1889 Zoothbrush (easy to grasp, fanciful toothbrushes) Susan Harrison 1993 Female Ingenuity A partial list of the many ingenious inventions by women. Invention Inventor Year Antifungal antibiotic (Nystatin) Rachel Fuller Brown and 1957 Elizabeth Lee Hazen Barbi Doll Ruth Handler 1959 Brassiere Mary Phelps Jacob 1913 Battery container Nancy Perkins 1986 Beehive Thiphena Hornbrook 1861 Cabinet Bed Sarah Goode 1885 Canister vacuum Nancy Perkins 1987 Brought to you by The Book Farm, Inc. Courtesy of factmonster.com For Ordering or More Information: 866-744-8093. 1 Car heater Margaret Wilcox 1893 Circular saw Tabitha Babbit 1812 COBOL (Common Business-Oriented Language) Grace Hopper 1959 Computer program Augusta Ada Byron 1842 Cooking stove Elizabeth Hawk 1867 CPR Mannequin Dianne Croteau, et al 1989 Dam and reservoir construction Harriet Strong 1887 Direct and return mailing envelope Beulah Henry 1962 Dishwasher Josephine Cochran 1872 Disposable cell phone Randi Altschul 1999 Drinking fountain device Laurene O'Donnell 1985 Electric hot water heater Ida Forbes 1917 Elevated railway Mary Walton 1881 Engine muffler El Dorado Jones 1917 Feedback control for data processing Erna Hoover 1971 Fire escape Anna Connelly 1887 Fireplace damper actuator Virgie Ammons 1975 Geobond Patricia Billings 1997 Globes Ellen Fitz 1875 "Gong and signal chair" Miriam Benjamin 1888 Grain storage bin Lizzie Dickelman 1920 Hair products for African Americans Madame C.J.
    [Show full text]
  • Guidelines for Atcvet Classification 2012
    Guidelines for ATCvet classification 2012 ISSN 1020-9891 ISBN 978-82-8082-479-0 Suggested citation: WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATCvet classification 2012. Oslo, 2012. © Copyright WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway. Use of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed. Guidelines for ATCvet classification 14th edition WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health P.O.Box 4404 Nydalen N-0403 Oslo Norway Telephone: +47 21078160 Telefax: +47 21078146 E-mail: [email protected] Website: www.whocc.no Previous editions: 1992: Guidelines on ATCvet classification, 1st edition1) 1995: Guidelines on ATCvet classification, 2nd edition1) 1999: Guidelines on ATCvet classification, 3rd edition1) 2002: Guidelines for ATCvet classification, 4th edition2) 2003: Guidelines for ATCvet classification, 5th edition2) 2004: Guidelines for ATCvet classification, 6th edition2) 2005: Guidelines for ATCvet classification, 7th edition2) 2006: Guidelines for ATCvet classification, 8th edition2) 2007: Guidelines for ATCvet classification, 9th edition2) 2008: Guidelines for ATCvet classification, 10th edition2) 2009: Guidelines for ATCvet classification, 11th edition2) 2010: Guidelines for ATCvet classification, 12th edition2) 2011: Guidelines for ATCvet classification, 13th edition2) 1) Published by the Nordic Council on Medicines 2) Published by the WHO Collaborating Centre for Drug Statistics Methodology Preface The Anatomical Therapeutic Chemical classification system for veterinary medicinal products, ATCvet, has been developed by the Nordic Council on Medicines (NLN) in collaboration with the NLN’s ATCvet working group, consisting of experts from the Nordic countries.
    [Show full text]
  • Luciano Polonelli
    Luciano Polonelli Department of Biomedical, Biotechnological and Translational Sciences, Unit of Microbiology and Virology, University of Parma, Parma, Italy Tel.: +39 0521 903429; Fax: +39 0521 993620; e-mail: [email protected] History of Medical Mycology File 2 (1895-1950) 1895 Giuseppe Marconi (1862-1940), born in Naples, Italy, Professor of Veterinary Pathology and Clinic in the Royal University of Pisa, Italy, isolated and cultivated for the first time Cryptococcus farciminosum, the agent of epizootic lymphangitis, in the form of sterile mycelium (1895). Piero Redaelli and Raffaele Ciferri transferred (1934) C. farciminosum to the genus Histoplasma, as H. farciminosum (Rivolta and Micellone 1883, Redaelli and Ciferri 1934), mainly because of its dimorphic nature that made it similar to the tissue form of H. capsulatum var. capsulatum Darling 1906. Robert J. Weeks, Arvind A. Padhye and Libero Ajello, at the Division of Mycotic Diseases, Center for Infectious Diseases, Centers for Disease Control (C.D.C.) Atlanta, Georgia, U.S.A. (1985), observed that this fungus generated macro- and microconidia resembling those of the capsulatum and duboisii varieties of H. capsulatum when incubated at room temperature, thus reducing the fungus to a varietal status as H. capsulatum var. farciminosum (Rivolta, 1873) Weeks, Padhye & Ajello, 1985. Raffaele Ciferri (1960) reduced Histoplasma duboisii (Vanbreuseghem, 1992) to varietal status as H. capsulatum var. duboisii (Vanbreuseghem, 1992), Ciferri, 1960 [Ajello, 1998; Marcone, 1895; Redaelli and Ciferri, 1934; Weeks et al., 1985]. 1 1896 The American surgeon Emmet Rixford (1865-1938), born in Bedford, Canada, first graduated in engineering and then Doctor in Medicine (1891), and Thomas C.
    [Show full text]